Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI Study

Matilde Sánchez‐Conde, Vincent Soriano(Fundación Instituto Valenciano de Oncología), Carmen de Mendoza, Rosario Palacios(Bellvitge University Hospital), Víctor Asensi(Baylor College of Medicine), Pablo Rivas(Hospital Universitario Fundación Jiménez Díaz), Sonia Rodríguez‐Nóvoa, Juan González‐Lahoz, José Sanz, Julio Sola(Complejo Hospitalario de Navarra), Inmaculada Jiménez‐Nácher(Rafael Advanced Defense Systems (Israel)), Pablo Barreiro(Hospital Clínico San Carlos), Jesús Santos(Hospital Clínico Universitario Virgen de la Victoria), Vicente Estrada(Instituto de Salud Carlos III)
AIDS Research and Human Retroviruses
February 2, 2007
10.1089/aid.2006.0029
Cited by 15

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel
|AIDS|2002|443
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
|The Lancet HIV|2020|396